Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

Lynn G. Feun, Christopher O'Brien, Enrique Molina, Miguel Rodriguez, Lenox Jeffers, Eugene R. Schiff, Angela Marini, Niramol Savaraj, Bach Ardalan

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)17-20
Number of pages4
JournalJournal of cancer research and clinical oncology
Volume129
Issue number1
StatePublished - Jan 1 2003

Keywords

  • 5FUDR
  • Doxorubicin
  • Hepatocellular carcinoma
  • Interferon

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial'. Together they form a unique fingerprint.

  • Cite this